IL1B and juvenile idiopathic arthritis: Of the 20 patients with systemic juvenile idiopathic arthritis who started a second biologic, eight (40%) patients started tocilizumab following initial treatment with an IL-1 inhibitor and six (30%) initiated treatment with an IL-1 inhibitor after initial treatment with tocilizumab (figure 2).